Drug Profile
Research programme: anticancer antibodies - Cancer Research Technology/Roche Glycart
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cancer Research UK
- Developer Cancer Research Technology; Cancer Research UK; Roche Glycart
- Class Antibodies
- Mechanism of Action Cell surface receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
- 17 Jan 2008 Preclinical trials in Cancer in United Kingdom (Parenteral)